Coseasonal Initiation of Allergen Immunotherapy: A Systematic Review

Creticos, Peter S.; Bernstein, David I.; Casale, Thomas B.; Lockey, Richard F.; Maloney, Jennifer; Nolte, Hendrik

doi:10.1016/j.jaip.2016.05.014

Cited by 23 publications

(9 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to a systematic review of the published literature on intra-seasonal initiation of AIT, no increase of AEs of concern was observed with SCIT and SLIT [3]. The feasibility and good tolerability of an intra-seasonal initiation of AIT with the SQ Ò grass SLIT tablet has been shown in a previous RDBPC trial and was confirmed by a large noninterventional study in real life [18,19].…”

Section: Discussionmentioning

confidence: 74%

“…Allergy immunotherapy (AIT) as a treatment option that has the potential to modify the allergic disease [1,2] is usually initiated after the end of the pollen season due to a presumed higher risk for side effects if allergens for therapy are administered while the patient is naturally exposed. In a recently published systematic review of the published literature on coseasonal initiation of treatment with AIT, no increase of the risk of systemic, serious or severe reactions was identified with subcutaneous (SCIT) and sublingual immunotherapy (SLIT) [3].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Intra-Seasonal Initiation of the SQ-Standardised Grass Allergy Immunotherapy Tablet Routinely Applied by Allergy Specialists and General Practitioners with Experience in Treatment of Allergy: A Non-Interventional Observational Study

Schwab¹,

Wolf

Schnitker

et al. 2018

Pulm Ther

View full text Add to dashboard Cite

Introduction: Intra-seasonal start of treatment with the SQ Ò grass sublingual immunotherapy (SLIT) tablet (GRAZAX Ò , ALK, Denmark) has been previously demonstrated to be well-tolerated. The objective of our study was to investigate the tolerability of intra-seasonal start of treatment comparing patients treated by allergists and general practitioners experienced in treatment of allergy (GPs). Methods: In a non-interventional, open-label, observational study, data on intra-seasonal start

show abstract

Section: Discussionmentioning

confidence: 74%

Section: Introductionmentioning

confidence: 99%

Intra-Seasonal Initiation of the SQ-Standardised Grass Allergy Immunotherapy Tablet Routinely Applied by Allergy Specialists and General Practitioners with Experience in Treatment of Allergy: A Non-Interventional Observational Study

Schwab¹,

Wolf

Schnitker

et al. 2018

Pulm Ther

View full text Add to dashboard Cite

show abstract

“…Presence of mild asthma did not affect adverse reactions for grass pollen SLIT tablets 2651 . Starting SLIT in‐season is generally deemed to be safe; although there were two serious treatment related adverse events with co‐seasonal SLIT initiation, none needed epinephrine 2650 …”

Section: Managementmentioning

confidence: 87%

International consensus statement on allergy and rhinology: Allergic rhinitis – 2023

Wise

Damask

Roland

et al. 2023

Int Forum Allergy Rhinol

157

View full text Add to dashboard Cite

Background In the 5 years that have passed since the publication of the 2018 International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (ICAR‐Allergic Rhinitis 2018), the literature has expanded substantially. The ICAR‐Allergic Rhinitis 2023 update presents 144 individual topics on allergic rhinitis (AR), expanded by over 40 topics from the 2018 document. Originally presented topics from 2018 have also been reviewed and updated. The executive summary highlights key evidence‐based findings and recommendation from the full document. Methods ICAR‐Allergic Rhinitis 2023 employed established evidence‐based review with recommendation (EBRR) methodology to individually evaluate each topic. Stepwise iterative peer review and consensus was performed for each topic. The final document was then collated and includes the results of this work. Results ICAR‐Allergic Rhinitis 2023 includes 10 major content areas and 144 individual topics related to AR. For a substantial proportion of topics included, an aggregate grade of evidence is presented, which is determined by collating the levels of evidence for each available study identified in the literature. For topics in which a diagnostic or therapeutic intervention is considered, a recommendation summary is presented, which considers the aggregate grade of evidence, benefit, harm, and cost. Conclusion The ICAR‐Allergic Rhinitis 2023 update provides a comprehensive evaluation of AR and the currently available evidence. It is this evidence that contributes to our current knowledge base and recommendations for patient evaluation and treatment.

show abstract

“…Nonetheless, the recent literature reports that a co-seasonal initiation of AIT and the reduction of doses do not increase the risk of adverse events [63]. …”

Section: Safety Aspectsmentioning

confidence: 99%

Clinical practice recommendations for allergen-specific immunotherapy in children: the Italian consensus report

et al. 2017

View full text Add to dashboard Cite

Allergen-specific immunotherapy (AIT) is currently recognized as a clinically effective treatment for allergic diseases, with a unique disease-modifying effect. AIT was introduced in clinical practice one century ago, and performed in the early years with allergenic extracts of poor quality and definition. After the mechanism of allergic reaction were recognized, the practice of AIT was refined, leading to remarkable improvement in the efficacy and safety profile of the treatment. Currently AIT is accepted and routinely prescribed worldwide for respiratory allergies and hymenoptera venom allergy. Both the subcutaneous (SCIT) and sublingual (SLIT) routes of administration are used in the pediatric population.AIT is recommended in allergic rhinitis/conjunctivitis with/without allergic asthma, with an evidence of specific IgE-sensitization towards clinically relevant inhalant allergens. Long-term studies provided evidence that AIT can also prevent the onset of asthma and of new sensitizations. The favorable response to AIT is strictly linked to adherence to treatment, that lasts 3–5 years. Therefore, several factors should be carefully evaluated before starting this intervention, including the severity of symptoms, pharmacotherapy requirements and children and caregivers’ preference and compliance.In recent years, there have been increasing interest in the role of AIT for the treatment of IgE-associated food allergy and extrinsic atopic dermatitis. A growing body of evidence shows that oral immunotherapy represents a promising treatment option for IgE-associated food allergy. On the contrary, there are still controversies on the effectiveness of AIT for patients with atopic dermatitis.This consensus document was promoted by the Italian Society of Pediatric Allergy and Immunology (SIAIP) to provide evidence-based recommendations on AIT in order to implement and optimize current prescription practices of this treatment for allergic children.

show abstract

Coseasonal Initiation of Allergen Immunotherapy: A Systematic Review

Cited by 23 publications

References 40 publications

Intra-Seasonal Initiation of the SQ-Standardised Grass Allergy Immunotherapy Tablet Routinely Applied by Allergy Specialists and General Practitioners with Experience in Treatment of Allergy: A Non-Interventional Observational Study

Intra-Seasonal Initiation of the SQ-Standardised Grass Allergy Immunotherapy Tablet Routinely Applied by Allergy Specialists and General Practitioners with Experience in Treatment of Allergy: A Non-Interventional Observational Study

International consensus statement on allergy and rhinology: Allergic rhinitis – 2023

Clinical practice recommendations for allergen-specific immunotherapy in children: the Italian consensus report

Contact Info

Product

Resources

About